Altered cholesterol and fatty acid metabolism in Huntington disease

Journal of Clinical Lipidology

Volumn 4, Issue 1, 2010, Pages 17-23

  Block, Robert C ^a   Dorsey, E Ray ^b   Beck, Christopher A ^b   Brenna, J  Thomas ^c   Shoulson, Ira ^b  

^a Division of Epidemiology   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^c Department of Obstetrics Gynecology   (United States)

Author keywords

Cholesterol; Huntington disease; Insulin resistance; Omega 3 fatty acids; Triglycerides

Indexed keywords

CHOLESTEROL; DOCOSAHEXAENOIC ACID; GLITAZONE DERIVATIVE; ICOSAPENTAENOIC ACID; METFORMIN; OMEGA 3 FATTY ACID; ROSIGLITAZONE; STEROL REGULATORY ELEMENT BINDING PROTEIN;

BODY MASS; CENTRAL NERVOUS SYSTEM; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL TRIAL; DIET SUPPLEMENTATION; DIETARY INTAKE; DISEASE ASSOCIATION; DISEASE COURSE; FATTY ACID METABOLISM; HUMAN; HUNTINGTON CHOREA; INSULIN RESISTANCE; LIPID METABOLISM; METABOLIC DISORDER; NERVE DEGENERATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT INDICATION; WEIGHT REDUCTION;

CENTRAL NERVOUS SYSTEM; CHOLESTEROL; FATTY ACIDS; FATTY ACIDS, OMEGA-3; HUMANS; HUNTINGTON DISEASE; INSULIN RESISTANCE; LIPID METABOLISM; MUTANT PROTEINS; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS;

ANIMALIA;

EID: 75849142894     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2009.11.003     Document Type: Review

References (48)

1. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 72 (1993) 971-983
2. Rubinsztein D.C., Amos W., Leggo J., et al. Mutational bias provides a model for the evolution of Huntington's disease and predicts a general increase in disease prevalence. Nat Genet 7 (1994) 525-530
3. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 66 (2006) 366-372
4. Lanska D.J., Lavine L., Lanska M.J., and Schoenberg B.S. Huntington's disease mortality in the United States. Neurology 38 (1988) 769-772
5. Saher G., Brugger B., Lappe-Siefke C., et al. High cholesterol level is essential for myelin membrane growth. Nat Neurosci 8 (2005) 468-475
6. Valenza M., and Cattaneo E. Cholesterol dysfunction in neurodegenerative diseases: is Huntington's disease in the list?. Prog Neurobiol 80 (2006) 165-176
7. Valenza M., Rigamonti D., Goffredo D., et al. Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. J Neurosci 25 (2005) 9932-9939
8. Sipione S., Rigamonti D., Valenza M., et al. Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses. Hum Mol Genet 11 (2002) 1953-1965
9. Markianos M., Panas M., Kalfakis N., and Vassilopoulos D. Low plasma total cholesterol in patients with Huntington's disease and first-degree relatives. Mol Genet Metab 93 (2008) 341-346
10. Lutjohann D., Breuer O., Ahlborg G., et al. Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc Natl Acad Sci USA 93 (1996) 9799-9804
11. Norlin M., Toll A., Bjorkhem I., and Wikvall K. 24-hydroxycholesterol is a substrate for hepatic cholesterol 7alpha-hydroxylase (CYP7A). J Lipid Res 41 (2000) 1629-1639
12. Menkes J.H., and Hanoch A. Huntington's disease-growth of fibroblast cultures in lipid-deficient medium: a preliminary report. Ann Neurol 1 (1977) 423-425
13. Torrejon C., Jung U.J., and Deckelbaum R.J. n-3 Fatty acids and cardiovascular disease: actions and molecular mechanisms. Prostaglandins Leukot Essent Fatty Acids 77 (2007) 319-326
14. Yanai A., Huang K., Kang R., et al. Palmitoylation of huntingtin by HIP14 is essential for its trafficking and function. Nat Neurosci 9 (2006) 824-831
15. Singaraja R.R., Hadano S., Metzler M., et al. HIP14, a novel ankyrin domain-containing protein, links huntingtin to intracellular trafficking and endocytosis. Hum Mol Genet 11 (2002) 2815-2828
16. Underwood B.R., Broadhurst D., Dunn W.B., et al. Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. Brain 129 (2006) 877-886
17. Steinberger J., Daniels S.R., Eckel R.H., et al. American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young, Council on Cardiovascular Nursing, and Council on Nutrition, Physical Activity, and Metabolism. Progress and challenges in metabolic syndrome in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in the Young Committee of the Council on Cardiovascular Disease in the Young; Council on Cardiovascular Nursing; and Council on Nutrition, Physical Activity, and Metabolism. Circulation 119 (2009) 628-647
18. Farrer L.A. Diabetes mellitus in Huntington disease. Clin Genet 27 (1985) 62-67
19. Lalic N.M., Maric J., Svetel M., et al. Glucose homeostasis in Huntington disease: abnormalities in insulin sensitivity and early-phase insulin secretion. Arch Neurol 65 (2008) 476-480
20. Tripathy D., Carlsson M., Almgren P., et al. Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study. Diabetes 49 (2000) 975-980
21. Hunt M.J., and Morton A.J. Atypical diabetes associated with inclusion formation in the R6/2 mouse model of Huntington's disease is not improved by treatment with hypoglycaemic agents. Exp Brain Res 166 (2005) 220-229
22. Rulifson E.J., Kim S.K., and Nusse R. Ablation of insulin-producing neurons in flies: growth and diabetic phenotypes. Science 296 (2002) 1118-1120
23. Riserus U. Fatty acids and insulin sensitivity. Curr Opin Clin Nutr Metab Care 11 (2008) 100-105
24. Cole G.M., Ma Q.L., and Frautschy S.A. Omega-3 fatty acids and dementia. Prostaglandins Leukot Essent Fatty Acids 81 (2009) 213-221
25. da Silva T.M., Munhoz R.P., Alvarez C., Naliwaiko K., Kiss A., Andreatini R., and Ferraz A.C. Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. J Affect Disord 111 (2008) 351-359
26. McCann J.C., and Ames B.N. Is docosahexaenoic acid, an n-3 long-chain polyunsaturated fatty acid, required for development of normal brain function? An overview of evidence from cognitive and behavioral tests in humans and animals. Am J Clin Nutr 82 (2005) 281-295
27. Huntington Study Group TREND-HD Investigators. Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch Neurol 65 (2008) 1582-1589
28. Murck H., and Manku M. Ethyl-EPA in Huntington disease: potentially relevant mechanism of action. Brain Res Bull 72 (2007) 159-164
29. Froyland L., Madsen L., Vaagenes H., et al. Mitochondrion is the principal target for nutritional and pharmacological control of triglyceride metabolism. J Lipid Res 38 (1997) 1851-1858
30. Esfandiari A., Soifiyoudine D., and Paturneau-Jouas M. Inhibition of fatty acid beta-oxidation in rat brain cultured astrocytes exposed to the neurotoxin 3-nitropropionic acid. Dev Neurosci 19 (1997) 312-320
31. Ait-Said F., Elalamy I., Werts C., et al. Inhibition by eicosapentaenoic acid of IL-1beta-induced PGHS-2 expression in human microvascular endothelial cells: involvement of lipoxygenase-derived metabolites and p38 MAPK pathway. Biochim Biophys Acta 1631 (2003) 77-84
32. Rhodes L.E., Shahbakhti H., Azurdia R.M., et al. Effect of eicosapentaenoic acid, an omega-3 polyunsaturated fatty acid, on UVR-related cancer risk in humans. An assessment of early genotoxic markers. Carcinogenesis 24 (2003) 919-925
33. Song C., Li X., Leonard B.E., and Horrobin D.F. Effects of dietary n-3 or n-6 fatty acids on interleukin-1beta-induced anxiety, stress, and inflammatory responses in rats. J Lipid Res 44 (2003) 1984-1991
34. Zimmer L., Hembert S., Durand G., et al. Chronic n-3 polyunsaturated fatty acid diet-deficiency acts on dopamine metabolism in the rat frontal cortex: a microdialysis study. Neurosci Lett 240 (1998) 177-181
35. Hibbeln J.R., Linnoila M., Umhau J.C., Rawlings R., George D.T., and Salem Jr. N. Essential fatty acids predict metabolites of serotonin and dopamine in cerebrospinal fluid among healthy control subjects, and early- and late-onset alcoholics. Biol Psychiatry 44 (1998) 235-242
36. Van Raamsdonk J.M., Pearson J., Rogers D.A., et al. Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. Exp Neurol 196 (2005) 266-272
37. Diau G.Y., Hsieh A.T., Sarkadi-Nagy E.A., Wijendran V., Nathanielsz P.W., and Brenna J.T. The influence of long chain polyunsaturate supplementation on docosahexaenoic acid and arachidonic acid in baboon neonate central nervous system. BMC Med 3 (2005) 11
38. Moriguchi T., Lim S.Y., Greiner R., et al. Effects of an n-3-deficient diet on brain, retina, and liver fatty acyl composition in artificially reared rats. J Lipid Res 45 (2004) 1437-1445
39. Chen C.T., Liu Z., Ouellet M., Calon F., and Bazinet R.P. Rapid b-oxidation of eicosapentaenoic acid in mouse brain: an in situ study. Prost Leukot Essent Fatty Acids 80 (2009) 157-163
40. Philbrick D.J., Mahadevappa V.G., Ackman R.G., and Holub B.J. Ingestion of fish oil or a derived n-3 fatty acid concentrate containing eicosapentaenoic acid (EPA) affects fatty acid compositions of individual phospholipids of rat brain, sciatic nerve and retina. J Nutr 117 (1987) 1663-1670
41. Serhan C.N., Chiang N., and Van Dyke T.E. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nat Rev Immunol 8 (2008) 349-361
42. Davidson M.H. Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids. Am J Cardiol 98 (2006) 27i-33i
43. Flachs P., Rossmeisl M., Bryhn M., and Kopecky J. Cellular and molecular effects of n-3 polyunsaturated fatty acids on adipose tissue biology and metabolism. Clin Sci (Lond) 116 (2009) 1-16
44. González-Périz A., Horrillo R., Ferré N., et al. Obesity-induced insulin resistance and hepatic steatosis are alleviated by {omega}-3 fatty acids: a role for resolvins and protectins. FASEB J (2009) 23:1946-1957
45. Harris W.S. N-3 Fatty acids and serum lipoproteins: human studies. Am J Clin Nutr 65 (1997) 1645S-1654S
46. Kris-Etherton P.M., Harris W.S., and Appel L.J. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 106 (2002) 2747-2757
47. Ma T.C., Buescher J.L., Oatis B., et al. Metformin therapy in a transgenic mouse model of Huntington's disease. Neurosci Lett 411 (2007) 98-103
48. Quintanilla R.A., Jin Y.N., Fuenzalida K., Bronfman M., and Johnson G.V. Rosiglitazone treatment prevents mitochondrial dysfunction in mutant huntingtin-expressing cells: possible role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in the pathogenesis of Huntington disease. J Biol Chem 283 (2008) 25628-25637